JCHAIN

Across TCGA pan-cancer cohorts, JCHAIN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated JCHAIN data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher JCHAIN mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated JCHAIN expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where JCHAIN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.922	0.999	.016	11	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.846	.015	8	view →
GBM	OS	Tertile	All	0.292	0.554	.020	6	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	6	view →
PDAC	OS	Quartile	All	1.000	0.800	.008	5	view →
UCEC	OS	Quartile	II,III,IV	0.367	1.000	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

JCHAIN–LUAD (OS)

Open the LUAD breakdown →